189 related articles for article (PubMed ID: 11012554)
1. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
Freyer G; Tranchand B; Ligneau B; Ardiet C; Souquet PJ; Court-Fortune I; Riou R; Rebattu P; Boissel JP; Trillet-Lenoir V; Girard P
Br J Clin Pharmacol; 2000 Oct; 50(4):315-24. PubMed ID: 11012554
[TBL] [Abstract][Full Text] [Related]
2. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT).
Freyer G; Ligneau B; Tranchand B; Ardiet C; Souquet PJ; Court-Fortune I; Riou R; Rebattu P; Morignat E; Boissel JP; Trillet-Lenoir V; Girard P
Lung Cancer; 2001; 31(2-3):247-56. PubMed ID: 11165404
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
Busse D; Würthwein G; Hinske C; Hempel G; Fromm MF; Eichelbaum M; Kroemer HK; Busch FW
Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):218-25. PubMed ID: 12172704
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
6. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
7. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
8. Au/Pd@rGO nanocomposite decorated with poly (L-Cysteine) as a probe for simultaneous sensitive electrochemical determination of anticancer drugs, Ifosfamide and Etoposide.
Hatamluyi B; Lorestani F; Es'haghi Z
Biosens Bioelectron; 2018 Nov; 120():22-29. PubMed ID: 30144642
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of total and unbound etoposide.
Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G; Corona G; Sorio R; Robieux I; Basso B; Colussi AM; Boiocchi M
Br J Clin Pharmacol; 2001 Nov; 52(5):511-9. PubMed ID: 11736859
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients.
Johnstone EC; Lind MJ; Griffin MJ; Boddy AV
Cancer Chemother Pharmacol; 2000; 46(6):433-41. PubMed ID: 11138456
[TBL] [Abstract][Full Text] [Related]
15. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
[TBL] [Abstract][Full Text] [Related]
18. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Leyvraz S; Perey L; Rosti G; Lange A; Pampallona S; Peters R; Humblet Y; Bosquée L; Pasini F; Marangolo M
J Clin Oncol; 1999 Nov; 17(11):3531-9. PubMed ID: 10550151
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters.
Gustafson DL; Thamm DH
J Vet Intern Med; 2010; 24(3):579-86. PubMed ID: 20337920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]